+

WO2001091625A3 - Methods and compositions for the diagnosis of schizophrenia - Google Patents

Methods and compositions for the diagnosis of schizophrenia Download PDF

Info

Publication number
WO2001091625A3
WO2001091625A3 PCT/US2001/013019 US0113019W WO0191625A3 WO 2001091625 A3 WO2001091625 A3 WO 2001091625A3 US 0113019 W US0113019 W US 0113019W WO 0191625 A3 WO0191625 A3 WO 0191625A3
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
methods
diagnosis
compositions
scz
Prior art date
Application number
PCT/US2001/013019
Other languages
French (fr)
Other versions
WO2001091625A2 (en
Inventor
Linda M Brzustowicz
Anne S Bassett
Original Assignee
Univ Rutgers
Linda M Brzustowicz
Anne S Bassett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers, Linda M Brzustowicz, Anne S Bassett filed Critical Univ Rutgers
Priority to AU2001255580A priority Critical patent/AU2001255580A1/en
Publication of WO2001091625A2 publication Critical patent/WO2001091625A2/en
Publication of WO2001091625A3 publication Critical patent/WO2001091625A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention maps a gene (SCZ) associated with schizophrenia to the q22 region of chromosome 1. The invention exploits this discovery to provide methods of diagnosing schizophrenia and schizophrenia susceptibility, methods of screening for the SCZ gene, and libraries of cloned segments including the SCZ gene.
PCT/US2001/013019 2000-04-21 2001-04-23 Methods and compositions for the diagnosis of schizophrenia WO2001091625A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001255580A AU2001255580A1 (en) 2000-04-21 2001-04-23 Methods and compositions for the diagnosis of schizophrenia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19889300P 2000-04-21 2000-04-21
US60/198,893 2000-04-21

Publications (2)

Publication Number Publication Date
WO2001091625A2 WO2001091625A2 (en) 2001-12-06
WO2001091625A3 true WO2001091625A3 (en) 2002-05-23

Family

ID=22735308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/013019 WO2001091625A2 (en) 2000-04-21 2001-04-23 Methods and compositions for the diagnosis of schizophrenia

Country Status (2)

Country Link
AU (1) AU2001255580A1 (en)
WO (1) WO2001091625A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072761A1 (en) * 2002-02-22 2003-09-04 Human Genome Sciences, Inc. 20 human secreted proteins
WO2006036445A2 (en) * 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHODS AND COMPOSITIONS FOR T CAR LYMPHOCYTE THERAPY
CN110612119B (en) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） Phosphatidylether (PLE) CAR T cell tumor targeting (CTCT) agents
CN112292138A (en) 2018-01-22 2021-01-29 西雅图儿童医院（Dba西雅图儿童研究所） Methods of use of CAR T cells
US12240870B2 (en) 2018-02-23 2025-03-04 Purdue Research Foundation Sequencing method for CAR T cell therapy
HUP1800441A1 (en) 2018-12-21 2020-06-29 Ferenc Benesch Activee chair, primarily for office use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRZUSTOWICZ L.A. ET AL.: "Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-22", SCIENCE, vol. 288, 28 April 2000 (2000-04-28), pages 678 - 682, XP002943618 *
GOODMAN A.B.: "Medical conditions in Ashkenazi schizophrenic pedigrees", SCHIZOPHRENIA BULLETIN, vol. 20, no. 3, 1994, pages 507 - 517, XP002946872 *
PULVER A.E. ET AL.: "Genetic heterogeneity in schizophrenia: Stratification of genome scan data using co-segregating related phenotypes", MOLECULAR PSYCHIATRY, vol. 5, November 2000 (2000-11-01), pages 650 - 653, XP002943617 *
WITTEKINDT O. ET AL.: "The human small conductance calcium-regulated potassium channel gene (HskcA3) contains two CAG repeats in exon 1, is on chromosome 1q21.3 and shows a possible association with schizophrenia", NEUROGENETICS, vol. 1, 1998, pages 259 - 265, XP002946870 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy

Also Published As

Publication number Publication date
AU2001255580A1 (en) 2001-12-11
WO2001091625A2 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
AU2001245945A1 (en) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
ATE347890T1 (en) DIARYLCYCLOALKYL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS PPAR ACTIVATORS
WO2002038806A3 (en) Detection of nucleic acid polymorphisms
WO2003107144A3 (en) Systems and methods for predicting oligonucleotide melting temperatures (tms)
WO2001064958A3 (en) Modified oligonucleotides for mismatch discrimination
CA2438574A1 (en) Method of detecting nucleotide polymorphism
AP2005003220A0 (en) Novel polymorph of N-Methyl-N-(3-{3-[2-Thienylcarbonyl]-Pyrazol-[1,5-Alpha]-Pyrimidin-7-YI}Phenyl) Acetanide and compositions and methods related thereto.
AU2002343573A1 (en) Methods for detecting genetic haplotypes by interaction with probes
WO2001091625A3 (en) Methods and compositions for the diagnosis of schizophrenia
WO2002044194A1 (en) L-nucleic acid derivatives and processes for the synthesis thereof
WO2001082774A3 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001087231A3 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001080721A3 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001082776A3 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001080720A3 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001080719A3 (en) Methods and composition for the diagnosis of schizophrenia
WO2001080717A3 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001080716A3 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001080718A3 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001082775A3 (en) Methods and compositions for the diagnosis of schizophrenia
WO2002002054A3 (en) Methods and compositions for the diagnosis of schizophrenia
WO2001080722A3 (en) Methods and compositions for the diagnosis of schizophrenia
NO20001510L (en) Specific immunophilin ligands such as anti-asthmatic, anti-allergic, anti-rheumatic, immunosuppressive, antipsychotic and neuroprotective agents
WO2003031641A3 (en) Beta 2 adrenergic polymorphism detection
WO1999017869A3 (en) Compositions for organic synthesis on solid phase and methods of using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载